74 related articles for article (PubMed ID: 3669290)
1. In vitro antimicrobial activity of cefpirome, a new cephalosporin with a broad antimicrobial spectrum.
Arai S; Kobayashi S; Hayashi S; Fujimoto K
Jpn J Antibiot; 1987 May; 40(5):969-82. PubMed ID: 3669290
[TBL] [Abstract][Full Text] [Related]
2. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum.
Iwahi T; Okonogi K; Yamazaki T; Shiki S; Kondo M; Miyake A; Imada A
Antimicrob Agents Chemother; 1992 Jul; 36(7):1358-66. PubMed ID: 1510428
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of a new semisynthetic cephalosporin: cefoperazone.
Auckenthaler R; Waldvogel FA
Clin Ther; 1980; 3(Spec Issue):89-97. PubMed ID: 6446401
[TBL] [Abstract][Full Text] [Related]
5. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefpirome (HR 810) against enterococci and staphylococci.
Piacentini E; Amalfitano G; Ligozzi M; Canepari P; Fontana R
J Chemother; 1992 Dec; 4(6):338-41. PubMed ID: 1287135
[TBL] [Abstract][Full Text] [Related]
8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
9. [HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin].
Chantot JF; Bryskier A
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):482-6. PubMed ID: 3937124
[TBL] [Abstract][Full Text] [Related]
10. [Cefpirome (HR 810). A new broad spectrum cephalosporin].
Bryskier A; Chantot JF
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):477-81. PubMed ID: 3937123
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antibacterial activity of the new semisynthetic cephalosporin cefpirome.
Mitsukude M; Inoue M; Mitsuhashi S
Arzneimittelforschung; 1989 Jan; 39(1):26-30. PubMed ID: 2785801
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of HR 810, a new broad-spectrum cephalosporin.
Machka K; Braveny I
Eur J Clin Microbiol; 1983 Aug; 2(4):345-9. PubMed ID: 6313358
[TBL] [Abstract][Full Text] [Related]
13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
[TBL] [Abstract][Full Text] [Related]
14. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Tumah H
Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antibacterial activity of cefpirome: a new cephalosporin; results of a multicenter study].
Soussy CJ; Chanal M; Derlot E; Goldstein F; Duval J
Pathol Biol (Paris); 1994 Oct; 42(8):754-60. PubMed ID: 7724247
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of HR 756, a new cephalosporin compound.
Shah PM; Troche G; Stille W
J Antibiot (Tokyo); 1978 Nov; 31(11):1170-4. PubMed ID: 102631
[TBL] [Abstract][Full Text] [Related]
17. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria.
Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M
J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706
[TBL] [Abstract][Full Text] [Related]
18. The antimicrobial activity in vitro of cefpirome and 6 other beta-lactam antibacterial agents against clinical isolates.
Yoshimura H; Kosaka Y; Hayashi T; Kawahara S
Jpn J Antibiot; 1993 Oct; 46(10):877-83. PubMed ID: 8254889
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
[TBL] [Abstract][Full Text] [Related]
20. [Antibiotic activities of cefpirome against fresh clinical isolates resistant to multiple drugs].
Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
Jpn J Antibiot; 1994 Feb; 47(2):143-60. PubMed ID: 8151908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
